Pridoksal Fosfatın Kolajen Tip VI İlişkili Miyopatilerde Potansiyel Tedavi Edici Etkisi

Year 2018, Volume: 1 Issue: 3, 111 - 115, 14.12.2018

İşıl Özer

https://doi.org/10.33713/egetbd.455485

Abstract

Giriş: Primer Hiperoksalüri Tip I (PH1) Pridoksal 5 Fosfat
bağımlı Alanin Gliksilat Aminotransferaz (AGT) 
enzimi bozukluğudur. Konjenital müsküler distrofiler (CMDs) nadir bir
kalıtsal hastalık grubudur. Ullrich Konjenital Müsküler Distrofi (UCMD) ciddi klinik
bulgusu olan CMD’lerden biridir.

Olgu: Oniki buçuk yaşında kız hasta hiperoksalüri bulgusu
ile başvurdu. Hastanın COL6A2 gen mutasyonlu UCMD hastalığı tanısı ile
izlenmekte olduğunu öğrendik. Aynı zamanda PH1 ile ilişkili AGT Pro 11 Leu/Ile
340 Met homozigot mutasyonu da bulundu. Pridoksal fosfat tedavisinden sonra, oksalozis
ile ilişkili cilt bulguları düzeldi, idrar oksalat/kreatinin oranı azaldı. Sürpriz
olarak, hastanın UCMD ile ilişkili kas bulguları da belirgin düzeldi. 

Tartışma: Pridoksal fosfatın, kollajen tip VI ile ilişkili
miyopatilerin günümüzde sadece semptomatik olan tedavisinde ne kadar etkili
olacağı konusunda ileri tetkikler yapılması gerektirmektedir.

Keywords

Kas distrofisi, hiperoksaluri, yeni tedavi metodu, pridoksin

References

• [1] Lorenz, E.C., Michet, C.J., Milliner, D.S., Lieske, J.C., 2013. Update on Oxalate Crystal Disease. Curr Rheumatol Rep. 15:340-344.
• [2] Zhao, F., et al., 2016. Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Clin J Am Soc Nephrol. 11:119-126.
• [3] Kuiper, J.J., 1996. Initial Manifestation of Primary Hyperoxaluria Type I in Adults Recognition, Diagnosis, and Management. West J Med. 164:42-53.
• [4] Bhasin, B., et al., 2015. Primary and secondary hyperoxaluria: understanding the enigma World J Nephrol.4:235-244.
• [5] Al Riyami, M.S., et al. 2105. Primary hyperoxaluria type I in 18 children: genotyping and outcome. Int J Nephrol. 2015:634175 Published online.
• [6] Taheri, D., Gheissari, A., Dolatkhah, S., 2015. Acute oxalate nephropathy following kidney transplantation: Report of three cases. J Res Med Sci. 20:818–823.
• [7] Kim, S., et al. 2015. A rare case of hyperoxaluria presenting with acute liver injury and stone-free kidney injury. Kidney Res Clin Pract. 34:113–116.
• [8] Falk, N., et al., 2013. Primary Hyperoxaluria Type 1 with Systemic Calcium Oxalate Deposition: Case Report and Literature Review. Ann Clin Lab Sci.43:328-331.
• [9] Berini, S.E., et al., 2015. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve. 51:449–454.
• [10] Moorhead, P.J., Cooper, D.J., 1975. Timperley WR. Progressive Peripheral Neuropathy in Patient with Primary Hyperoxaluria. British Med J. 2:312-313.
• [11] Bönnemann, C.G., 2011. The collagen VI-related myopathies: Ullrich congenital muscular dystrophy and Bethlem myopathy. Handb Clin Neurol.101:81–96.
• [12] Yonekawa, T., Nishino, I., 2015. Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s). J Neurol Neurosurg Psych.86:280-287.
• [13] Martín, P.J., et al., 2013. A Rare Case of Cardiomyopathy by Accumulation of Oxalate in a 53-Year-Old Woman. J Am Coll Card. 62:525.
• [14] Blackmon, J.A., et al., 2011. Oxalosis Involving the Skin: A Case Report and Literature Review. Arch Dermatol.147:1302-1305.
• [15] Cochat, P., et al., 1999. Combined liver-kidney transplantation in primary hyperoxaluria type 1. Eur. J. Pediatr., 158 :75-80.
• [16] Martin-Higueras, C., Luis-Lima, S., Salido, E., 2016. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of Primary Hyperoxaluria Type I. Mol Ther. 24:719-725.
• [17] Bushby, K.M., Collins, j., Hicks, D., 2014. Collagen type VI myopathies. Adv Exp Med Biol.802:185-199.
• [18] Demir, E. et al., 2002. Mutations in COL6A3 Cause Severe and Mild Phenotypes of Ullrich Congenital Muscular Dystrophy. Am J Hum Genet.70:1446–1458.
• [19] Paco, S. et al., 2013. Gene Expression Profiling Identifies Molecular Pathways Associated with Collagen VI Deficiency and Provides Novel Therapeutic Targets. PLoS ONE. 8: e77430.
• [20] Urciuolo, A., et al., 2013. Collagen VI regulates satellite cell self-renewal and muscle regeneration. Nat Commun.4:1964.
• [21] Grumati, P., Coletto, L., Bonaldo, P., 2011. Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. Autophagy.7:1415-1423.
• [22] Bernardi, P., Bonaldo, P., 2013. Mitochondrial Dysfunction and Defective Autophagy in the Pathogenesis of Collagen VI Muscular Dystrophies. Cold Spring Harb Perspect Biol.5: 011387.
• [23] Foley, A.R., et al., 2013. Natural history of pulmonary function in collagen VI-related myopathies. Brain.136:3625–3633.
• [24] Irwin, W.A., et al., 2003. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nature Genetics.35:367 – 371.
• [25] Chrisam, M., et al., 2015. Reactivation of autophagy by spermidine ameliorates the myopathic defects of collagen VI-null mice. Autophagy.11:2142-2152.
• [26] Palma, E., et al., 2009. Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice. Hum Mol Gen.18:2024–2031.
• [27] Alexeev, V., et al., 2014. Human adipose-derived stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy. Stem Cell Res Therapy.;5:5-21.
• [28] Angelin, A., et al., 2007. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. PNAS. 104:991–996.
• [29] Carsten, J.C., Bönnemann, G., 2010. Congenital Muscular Dystrophies: Toward Molecular Therapeutic Interventions. Curr Neur Neurosci Rep.10:83–91.
• [30] Merlini, L. et al., 2008. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. PNAS.105:5225–5229.